ES2570158T3 - Tratamiento de la isquemia de extremidades - Google Patents

Tratamiento de la isquemia de extremidades

Info

Publication number
ES2570158T3
ES2570158T3 ES10703115T ES10703115T ES2570158T3 ES 2570158 T3 ES2570158 T3 ES 2570158T3 ES 10703115 T ES10703115 T ES 10703115T ES 10703115 T ES10703115 T ES 10703115T ES 2570158 T3 ES2570158 T3 ES 2570158T3
Authority
ES
Spain
Prior art keywords
limb ischemia
treatment
disease
critical limb
buerger
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10703115T
Other languages
English (en)
Inventor
John Sinden
Erik Miljan
Paolo Madeddu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Reneuron Ltd
Original Assignee
Reneuron Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reneuron Ltd filed Critical Reneuron Ltd
Application granted granted Critical
Publication of ES2570158T3 publication Critical patent/ES2570158T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0623—Stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)

Abstract

El uso de células madre neuronales en la fabricación de un medicamento para el tratamiento de un paciente que padece arteriopatía periférica, en el que la enfermedad es isquemia de extremidades aguda o crítica, enfermedad de Buerger o isquemia de extremidades crítica en la diabetes.
ES10703115T 2009-02-06 2010-02-05 Tratamiento de la isquemia de extremidades Active ES2570158T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0902034.8A GB0902034D0 (en) 2009-02-06 2009-02-06 Method
PCT/GB2010/050185 WO2010089605A1 (en) 2009-02-06 2010-02-05 Treatment of limb ischemia

Publications (1)

Publication Number Publication Date
ES2570158T3 true ES2570158T3 (es) 2016-05-17

Family

ID=40469746

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10703115T Active ES2570158T3 (es) 2009-02-06 2010-02-05 Tratamiento de la isquemia de extremidades

Country Status (8)

Country Link
US (2) US8932577B2 (es)
EP (1) EP2393920B1 (es)
JP (2) JP5845089B2 (es)
AU (1) AU2010212147B2 (es)
CA (1) CA2747308C (es)
ES (1) ES2570158T3 (es)
GB (1) GB0902034D0 (es)
WO (1) WO2010089605A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0822246D0 (en) 2008-12-05 2009-01-14 Reneuron Ltd Composition
GB0902034D0 (en) 2009-02-06 2009-03-11 Reneuron Ltd Method
MX348419B (es) 2010-08-19 2017-06-12 F Hoffmann-La Roche Ag * Conversion de celulas somaticas a celulas madre, neurales reprogramadas, inducidas (irnscs).
EP2840957B1 (en) * 2012-04-27 2024-01-03 Stryker European Operations Limited Optical coherent imaging medical device and method

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4125373A1 (de) 1991-07-31 1993-02-04 Siemens Ag Sensorschlauch zur ueberwachung eines mediums
GB9518606D0 (en) 1995-09-12 1995-11-15 Inst Of Psychiatry Neural transplantation
US5968829A (en) 1997-09-05 1999-10-19 Cytotherapeutics, Inc. Human CNS neural stem cells
EP1060242A4 (en) * 1998-01-23 2003-09-17 Imclone Systems Inc PURIFIED POPULATIONS OF STEM CELLS
JP4740452B2 (ja) 1998-03-18 2011-08-03 オシリス セラピューティクス，インコーポレイテッド 移植で免疫応答の予防と処置のための間葉幹細胞を利用する方法、組成物およびその使用法
US6045990A (en) 1998-07-09 2000-04-04 Baust; John M. Inclusion of apoptotic regulators in solutions for cell storage at low temperature
WO2000018414A1 (en) 1998-09-29 2000-04-06 Diacrin, Inc. Transplantation of neural cells for the treatment of ischemic damage due to stroke
GB9904281D0 (en) 1999-02-24 1999-04-21 Reneuron Ltd Transplantation
GB9907243D0 (en) 1999-03-29 1999-05-26 Reneuron Ltd Therapy
US6399384B1 (en) 1999-09-17 2002-06-04 Reneuron Limited Conditional immortalization of cells
US6465215B1 (en) 1999-12-14 2002-10-15 Reneuron Limited Identification of cells for transplantation
US20070048726A1 (en) 2000-01-14 2007-03-01 Biolife Solutions, Inc. Methods and Compositions for the Control of Molecular-Based Cell Death During Preservation of Cells, Tissues or Organs in a Gel-Like State
DE60142553D1 (de) 2000-02-11 2010-08-26 Children S Hospital Of Orange Isolierung und transplantation von retinalen stammzellen
JP2002171965A (ja) * 2000-12-04 2002-06-18 Kansai Tlo Kk 骨髄単核球細胞の分離、濃縮方法及び血管再生剤
GB0125773D0 (en) 2001-10-26 2001-12-19 Reneuron Ltd Constructs
JP2005514926A (ja) * 2002-01-14 2005-05-26 ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ 新規ほ乳類多分化能幹細胞および組成物、その調製方法および投与方法
EP1576117A4 (en) 2002-07-19 2006-02-01 Vesta Therapeutics Inc METHOD FOR OBTAINING VIABLE HUMAN LIVER CELLS, INCLUDING STEM CELLS / HEPATIC PRECURSORS
US7470538B2 (en) 2002-12-05 2008-12-30 Case Western Reserve University Cell-based therapies for ischemia
WO2005014792A2 (en) 2003-08-08 2005-02-17 The General Hospital Corporation D/B/A Massachusetts General Hospital Preservation of biomaterials with transported preservation agents
CA2536655A1 (en) 2003-09-12 2005-03-24 Reneuron Limited Immortalisation of mammalian cells and therapeutic applications of said cells
JP4481706B2 (ja) 2004-03-31 2010-06-16 独立行政法人科学技術振興機構 脳梗塞疾患モデルマウス
GB0420963D0 (en) 2004-09-21 2004-10-20 Reneuron Ltd Hepatocyte
ES2294650T3 (es) 2004-09-30 2008-04-01 Reneuron Limited Linea celular.
WO2006055685A2 (en) * 2004-11-17 2006-05-26 Neuralstem, Inc. Transplantation of human neural cells for treatment of neurodegenerative conditions
JP4734669B2 (ja) 2005-02-04 2011-07-27 独立行政法人産業技術総合研究所 ヒト歯乳頭からの幹細胞及びその利用方法
CA2609507C (en) 2005-05-26 2014-10-21 Intercytex Limited Tissue repair using allogenic dermal fibroblasts
WO2006130433A2 (en) 2005-05-27 2006-12-07 Viacell, Inc. Treatment of ischemia using stem cells
JP2009502308A (ja) * 2005-07-28 2009-01-29 ブレインガード・カンパニー・リミテッド 幹細胞構造支持体としての炭素ナノチューブ
EP1789435B1 (en) 2005-09-12 2010-02-24 Industry Foundation of Chonnam National University A method for production of mature natural killer cell
GB0522564D0 (en) 2005-11-04 2005-12-14 Reneuron Ltd Cells
GB0703188D0 (en) 2007-02-19 2007-03-28 Roger Land Building Large scale production of stem cells
WO2008152640A2 (en) 2007-06-13 2008-12-18 Pluristem Ltd. Three dimensional biocompatible scaffolds for ex-vivo expansion and transplantation of stem cells
KR20100042654A (ko) * 2007-08-08 2010-04-26 교와 핫꼬 기린 가부시키가이샤 단리된 세포 집단
ES2588438T3 (es) 2008-03-27 2016-11-02 Biolife Solutions, Inc. Materiales y métodos para la recogida hipotérmica de sangre entera
GB0822246D0 (en) 2008-12-05 2009-01-14 Reneuron Ltd Composition
GB0902034D0 (en) * 2009-02-06 2009-03-11 Reneuron Ltd Method
GB201011589D0 (en) 2010-07-09 2010-08-25 Reneuron Ltd Therapeutic cells

Also Published As

Publication number Publication date
JP2014167017A (ja) 2014-09-11
AU2010212147A1 (en) 2011-07-07
US8932577B2 (en) 2015-01-13
JP5845089B2 (ja) 2016-01-20
EP2393920A1 (en) 2011-12-14
WO2010089605A1 (en) 2010-08-12
US20120093786A1 (en) 2012-04-19
EP2393920B1 (en) 2016-02-03
US9410122B2 (en) 2016-08-09
AU2010212147B2 (en) 2014-03-20
JP2012516884A (ja) 2012-07-26
US20140341868A1 (en) 2014-11-20
GB0902034D0 (en) 2009-03-11
CA2747308C (en) 2017-01-03
CA2747308A1 (en) 2010-08-12

Similar Documents

Publication Publication Date Title
GT200900095A (es) Dihidropirazolonas sustituidas para el tratamiento de enfermedades cardiovasculares y hermatologicas.
DOP2007000102A (es) Arilimidazolonas y ariltriazolona sustituidas asi como su uso
BRPI0618239A8 (pt) uso de flibanserina para o tratamento de distúrbios de desejo sexual pré-menopáusicos
UY32030A (es) "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
ES2721448T3 (es) GLYX-13 para uso en el tratamiento de enfermedad de Alzheimer, enfermedad de Parkinson y enfermedad de Huntington
GT200900230A (es) 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y uso
GT201200313A (es) 5-fluoro-1h-pirazolopiridinas sustituidas y su uso
AR060880A1 (es) Uso de flibanserina para el tratamiento de trastornos posmenopausicos del deseo sexual
CY1112320T1 (el) Τιτλοδοτηση της ταπενταδολης
EA201300213A1 (ru) Применение ингибиторов dpp iv
UY32177A (es) Tratamiento de diabetes en pacientes con control glucémico insuficiente a pesar de la terapia con fármaco, oral o no, antidiabético
CL2012000185A1 (es) Compuestos derivados de oxazina o oxazepina, inhibidores de bace; composicion farmaceutica que los comprende; combinacion farmaceutica; y su uso para el tratamiento del deterioro cognitivo, neuropatia amiloide, o enfermedad de alzheimer.
EA200900177A1 (ru) Замещенные ациланилиды и способы их применения
PA8784101A1 (es) Oxazolidinonas sustituidas y su uso
EA201100335A8 (ru) Производные пурина для применения при лечении связанных с fab заболеваний
SV2006002218A (es) Fenilaminotiazoles sustituidos y su uso ref.bhc041280-sv
EA200601777A1 (ru) Новое применение пептидных соединений для лечения боли при болезненной диабетической нейропатии
CL2007002382A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento del cancer a la piel.
BR112012006010A2 (pt) composto de glicina
GT200600109A (es) Derivados de acido pirimidincarboxilico y su uso
AR061446A1 (es) Utilizacion de la 1,7 -dimetilxantina para la fabricacion de un medicamento psicoanaleptico no ansiogeno destinado al tratamiento de un trastorno neuropsiquiatrico
GT200900319A (es) (oxazolidinon-5-il-metil)-2-tiofen-carboxamidas sustituidas y su uso en el campo de la coagulación sanguínea
CL2007002380A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento terapeutico y/o profilactico de la queratosis actinica.
UY29417A1 (es) Agentes endoparasiticidas
EP2364711A4 (en) USE OF EXTRACTS FROM BUNK SKIN INFLAMMATED WITH VACCINE VIRUS FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF ACUTE CEREBROVASCULAR DISEASE